79472-21-2Relevant academic research and scientific papers
METHODS OF TREATING NEURODEGENERATIVE DISEASES
-
, (2020/03/23)
Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.
ASK1 INHIBITOR COMPOUNDS AND USES THEREOF
-
, (2019/07/20)
Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.
New tetracyclic compound
-
, (2019/11/14)
The invention relates to a new tetracyclic compound. The tetracyclic compound has a structure shown in the formula (III) and can be used as a bromine domain and additional terminal (BET) inhibitor. The invention further relates to synthesis and application of the compounds in disease treatment. More specifically, the invention relates to a fused heterocyclic derivative used as a BET inhibitor, a method for the preparation of these compounds, and a disease and symptom treatment method conductive to inhibition of one or more BET bromine domains.
HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
-
, (2016/05/02)
The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
(2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol-5-yl)ketone derivative, preparation and uses thereof
-
, (2016/10/08)
The present invention discloses a (2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol-5-yl)ketone derivative, preparation and uses thereof, and particularly relates to a (2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0166, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF
-
, (2012/03/26)
Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
MST1 KINASE INHIBITORS AND METHODS OF THEIR USE
-
, (2012/09/11)
Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.
IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
-
, (2008/06/13)
Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
Aminomethylthiophene-2-carboxylic acids as dipeptide mimetic in new growth hormone secretagogues
Peschke, Bernd,Madsen, Kjeld,Hansen, Birgit Sehested,Johansen, Nils Langeland
, p. 1969 - 1972 (2007/10/03)
3-Aminomethylbenzoic acid is a well established dipeptide mimetic. Herein, aminomethylthiophene-2-carboxylic acids have been synthesized as analogues of 3-aminomethylbenzoic acid. Their use as a dipeptide-mimetic at the N-terminal of novel growth hormone secretagogues is described.
